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Cancer theranostics is a recent concept that aims to combine in the same device diagnostic and therapeutic
features. Magnetic nanoparticles (mNPs) are commonly used as a critical part of these systems due to their ability
to respond to an external magnetic field. Consequently, mNPs can generate heat when an alternating magnetic
field is applied and enhance image contrast in magnetic resonance. However, direct administration of mNPs
intravenously or directly in the tumor can lead to undesired side effects because of mNP elimination by macro-
phages or leakage to healthy tissues. Therefore, mNPs can be retained in a polymeric nanofibrous mesh, thus
preventing misplacing or loss of mNPs. Furthermore, these magnetic nanofibers can be directly implanted in the
tumor site, thus ensuring high mNPs loading and higher magnetic response. In addition, polymeric nanofibers
produced by electrospinning are frequently used to maintain a sustained drug release in the tumor site. Therefore,
a magnetic polymeric nanofiber produced by electrospinning is an ideal nanosystem for cancer theranostics
application. This review summarizes the most recent developments of magnetic nanofibers produced by elec-
trospinning for cancer theranostics applications.1. Introduction
Cancer is a significant burden on modern society, being the second
cause of death worldwide. According to the most recent data from Glo-
bocan, in 2020, approximately 19.3 million new cases were diagnosed. In
the same year, almost 10 million deaths worldwide were caused by
cancer diseases [1]. Despite this terrible scenario, cancer treatment and
diagnostic have been significantly improved over the last decades,
resulting in an increase of 5-year prevalence and survival rates. However,
several limitations are still associated with current treatments. Addi-
tionally, the increasing incidence and higher disease heterogeneity
motivate cancer research, focusing on a better understanding of the
disease, and developing new and improved strategies for cancer early
diagnostic and effective treatment [2].
New devices have been developed in recent years aiming at
combining in the same platform diagnostic and therapeutic features, i.e.,
theranostics devices. These theranostics devices are designed to act as a
personalized approach, leading to faster and more effective diagnostic
and treatment of a disease, namely cancer [3]. New and improved ma-
terials, particularly nanomaterials, have been used to produce thera-
nostics devices for cancer. In particular, nanofibers have attractedrm 5 November 2021; Accepted
ociety. Published by Elsevier B
rges, Recent advances in magn
ttps://doi.org/10.1016/j.pnsc.considerable attention as drug delivery systems for localized cancer
treatment. Nanofibers are included in one-dimensional nanomaterials,
i.e., nanomaterials with two dimensions within the nanoscale [4].
Therefore, nanofibers exhibit several advantages for biomedical appli-
cations: large specific surface area, tunable porosity, flexible surface
functionality, among others [5]. Electrospinning is a widely used tech-
nique to produce nanofibers. This simple and low-cost technique can
process different types of materials (polymer, ceramic) and electrospun
nanofibers have been used in various areas, including cancer theranostics
applications [6]. In this context, electrospun nanofibers are typically used
as localized drug delivery systems. Once loaded with an anti-cancer drug,
nanofibers can provide a sustained drug release at the tumor site. Addi-
tionally, nanofibers can be implanted directly at the tumor site following
surgery, thus reducing the risk of local recurrence of cancer [7].
Magnetic nanoparticles (mNPs) have a significant potential for
application in cancer theranostics due to their ability to respond to an
external magnetic field. Consequently, mNPs may be used for cancer
treatment as magnetic hyperthermia agents or triggers for drug release
and cancer diagnostic as imaging probes [8–10]. Magnetic nanofibers
can be composed of only magnetic materials or magnetic nanoparticles
embedded in a polymeric fiber. The latter is the most explored11 November 2021
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produce magnetic nanofibers [4].
This review will give an overview of the most recent advances in the
development of cancer theranostics nanosystems based on electrospun
nanofibers and magnetic nanoparticles. A brief overview of electro-
spinning technique will be given, followed by the typical application of
electrospun fibers in cancer theranostics. The following subsection in-
cludes a short description of mNPs properties and their functionality for
cancer theranostics applications. Finally, the most recent advances in
magnetic electrospun nanofibers are given. It is not our intention to
provide a complete description of the electrospinning process and mNPs
properties. For that, the reader is invited to read review papers dedicated
to these matters [5,11,12].
2. Electrospinning technique
Polymeric nanofibers can be produced by various methods, including
physical, chemical, and biological ones. From the available physical
methods, electrospinning is the most used technique because it was the
first method used to produce polymeric nanofibers [13] and its numerous
advantages. These advantages include its simplicity and low cost, avoids
the use of heat during fiber production, the possibility of modifying the
nanofibers, and easy incorporation of drugs or other bioactive substances
[11]. Electrospinning technique (Fig. 1) processes a polymeric melt or
solution to produce nanofibers with high surface area, controlled
porosity, and controllable size [7]. The method is based on applying a
high voltage to a needle (attached to a syringe containing the starting
material), thus inducing charges at the liquid surface, leading to a strong
electric field between the needle and the collector. Above a critical
voltage, the surface tension of the liquid is surpassed by the repulsive
electrostatic force, ejecting a charged jet of fluid towards the collector.
When the material is collected, an interconnected web of nanofibers is
obtained as a consequence of solvent evaporation (if the starting material
is a solution) or solidification (if the starting material is a melt) [13,14].
The final architecture of the fibers is determined by instabilities (whip-
ping or splitting) of the polymeric solution caused by Coulomb in-
teractions in the charged fluid. Therefore, the final fiber architecture can
be tailored by adjusting the processing parameters during electro-
spinning process [11,15].Fig. 1. Schematic representation of the electrospinning process including a high vo
needle, a syringe pump, and a collector where the polymeric fibers are deposited (R
2
2.1. Processing parameters
The processing parameters that primarily affect fiber morphology and
diameter can be divided into three main groups: solution properties,
processing parameters, and environmental conditions. Solution proper-
ties include polymer concentration, viscosity, surface tension, conduc-
tivity, dielectric constant, and solvent volatility. Polymer solution
concentration and viscosity are closely related and interdependent [15].
A minimum solution concentration is required for fiber formation during
electrospinning process. Low concentration tends to produce electro-
spray or beaded fibers, which is directly related to low viscosity. Viscosity
increase due to higher polymer concentration leads to an increase in
chain entanglement among the polymeric chains. These entanglements
aid in overcoming surface tension, thus producing uniform beadless fi-
bers. Ideal viscosity values are reported between 1 and 215 Poise to
produce uniform electrospun fibers, although most studies report good
fiber production between 1 and 20 Poise [16]. Polymer molecular weight
mainly affects solution viscosity and fiber morphology. High molecular
weight polymers tend to cause extensive chain entanglement, thus pro-
ducing uniform and larger fibers [17]. Polymer solution conductivity is
mainly dependent on intrinsic polymer properties, solvent, and ionizable
salts. An increase in electric conductivity tends to decrease fiber diameter
[18]. However, above a critical point, it may prevent the formation of
Taylor cone and fiber formation. Highly conductive solutions become
very unstable in the presence of strong electric fields, resulting in a
dramatic bending instability and a broad diameter distribution [19].
As for the processing parameters, the applied voltage directly affects
the dynamics of liquid flow, with significant consequences to fiber
morphology (particularly its diameter). Typically, an increase in the
applied voltage leads to smaller diameter fibers due to increased charge
repulsion in the polymer jet. However, above a critical value (which
depends on the polymer solution), irregular and beaded fibers can be
formed [20]. The capillary tip to collect distance will determine the
evaporation rate and the whipping or instability interval, resulting in
different fiber morphologies. Usually, a distance between 10 and 20 cm is
needed to produce homogenous fibers without defects. However, this
distance is intimately dependent on the electric field [21]. The flow rate
determines the amount of polymer solution available at the needle tip to
form the Taylor cone. There is a critical flow rate to produce uniformltage power supply, a syringe containing the polymeric solution attached to the
eprinted from Ref. [4] with permission from Elsevier).
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When the flow rate increases, the fiber diameter tends to increase as well.
An increase in flow rate increases the electric current and decreases the
surface charge density. The increase of volume being accelerated towards
the collector can lead to incomplete solvent evaporation, originating
bead formation, and irregular fibers [22].
Environmental conditions are determined mainly by relative hu-
midity and temperature, directly related to solvent evaporation and fiber
morphology. Nevertheless, these conditions are dependent on the
chemical nature of the polymer [21]. Low humidity results in a higher
solvent evaporation rate, originating thinner fibers. Higher temperatures
can have the same effect. However, in some cases, the opposite effect can
be observed. For example, Pelipenko et al. [23] demonstrated that an
increase in relative humidity leads to thinner fibers composed of a blend
between poly(vinyl alcohol) (PVA) and poly(ethylene oxide) (PEO).
Other authors also reported the same effect in plain PEO fibers. In fact, in
hydrophobic polymers, an increase in humidity can disrupt fiber
morphology due to water condensation at the fiber surface, leading to
pore formation [21].2.2. Application in cancer treatment and diagnostics
Electrospun fibers produced using biocompatible and biodegradable
materials have several advantages for biomedical applications. Electro-
spinning has been used as a processing technique to create cancer
theranostics devices mainly due to the possibility of incorporating a wide
range of biofunctional compounds into a nanostructure through a simple
approach [24]. For cancer treatment, the potential to have carriers for
local and targeted delivery of drugs, proteins, nucleic acids, and cells
supports the application of electrospun membranes. These membranes
are usually implantable systems with unique advantages like high and
adjusted dosage at the tumor site, decreased side effects in adjacent tis-
sues, and the possibility of effectively controlling drug release [6].
Different polymers can be used to encapsulate bioactive compounds
for cancer treatment purposes. Depending on the polymer chemical3
composition, the final nanofibrous membrane can have stimuli-
responsive properties, providing a higher degree of control over drug
release rate and mechanisms. Both natural and synthetic polymers can be
processed by electrospinning technique. Natural polymers include poly-
saccharides (chitosan, cellulose, among others) and their derivatives,
proteins (gelatin, collagen, among others), and DNA. On the other hand,
synthetic polymers that can be manipulated to match the desired prop-
erties include, for example, poly(lactic acid) (PLA), poly(lactic-co-gly-
colic acid) (PLGA), PEO, poly(ε-caprolactone) (PCL) [25]. PLA is widely
used for biomedical applications due to its biocompatibility and
non-toxic properties. Furthermore, due to its compatibility with bioactive
compounds, PLA is an efficient matrix for controlled drug release through
predictable kinetics. Zeng et al. [26] produced poly(l-lactide) (PLLA)
nanofibers through electrospinning to evaluate the encapsulation effi-
ciency and kinetics of drug release using three model drugs: paclitaxel,
doxorubicin hydrochloride, and doxorubicin (DOX). Both paclitaxel and
doxorubicin are lipophilic, while doxorubicin hydrochloride has a hy-
drophilic nature. The authors observed a preferable encapsulation of
lipophilic drugs, with release kinetics following nearly a zero-order ki-
netics dependent on polymer degradation. Doxorubicin hydrochloride
had a preferable localization at the fiber surface, leading to a burst
release dictated by diffusion. Similarly, when curcumin is loaded into
PLLA fibers, the release rate is mainly dictated by polymer degradation,
leading to a slow and controlled release of this anti-cancer drug [27]. In a
different study, Zhang et al. [28] produced a multilayer nanofiber mat
using PLLA loaded with two different drugs (oxaliplatin and dichlor-
oacetate) in distinct layers (Fig. 2A–C). This multilayer system can be
implanted in the tumor site following resection (Fig. 2 D), demonstrating
a synergistic effect between two drugs and the reduction of toxicity to
adjacent healthy tissues throughout 30-days.
PLA is often used in combination with poly(ethylene glycol) (PEG) to
produce an amphiphilic diblock co-polymer that can be processed by
emulsion electrospinning, originating fibers able to incorporate both
hydrophilic or lipophilic drugs. Xu et al. [29] used this technique to
incorporate doxorubicin into PEG-PLA nanofibers and evaluate theFig. 2. Scanning electron microscopy (SEM) of
PLLA fibers containing dichloroacetate (A) or oxa-
liplatin (B); C) cross-section of the multilayer PLLA
mat containing a PLLA film layer (a), a layer con-
taining oxaliplatin (b) followed by a plain PLLA
layer (c), and a dichloroacetate-containing layer. D)
Schematic representation of the experimental
outline of in vivo studies using the multilayer PLLA
mat: following cervical carcinoma resection, the
PLLA multilayer mat is implanted (Reprinted from
Ref. [28] with permission from Elsevier).
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the drug was homogeneously dispersed in the fiber core, forming a
core-shell nanofiber (Fig. 3 A, B). The drug release mechanism could be
divided into three parts, in which the first one showed a slower release
rate compared to the second part, although in both cases, the release
mechanism was based on Fick's second law. The authors concluded that
these amphiphilic nanofibers could act as a drug reservoir leading to a
controlled and slower release rate. The same fiber architecture was used
to obtain a sustained release of 2-hydroxypropyl—cyclodextrin for local
treatment of hepatic tumors [30].
Natural polymers are also commonly used to produce electrospun
nanofibers for cancer treatment purposes. Ignatova et al. [31] encapsu-
lated DOX in a nanofibrous mat composed of quaternized chitosan and
PLA (Fig. 3 C, D). The authors evaluated the antitumoral effect of these
membranes against a human cervical cancer cell line (HeLa) and a human
breast cancer cell line [34], demonstrating that cell death is mainly
achieved by apoptosis. A similar nanofibrous membrane caused a sig-
nificant reduction in Graffi cell viability in vivo through the same cell
death mechanism. Moreover, the combination of doxorubicin with qua-
ternized chitosan significantly reduces the adverse side effects [35].
Other polymers are also used to produce electrospun nanofibers as
controlled drug delivery systems for cancer treatment. For example,
Rasouli et al. [36] demonstrated that co-encapsulation of curcumin and
chrysin into PLGA-PEG nanofibers leads to a synergistic antiproliferative
effect against T47D breast cancer cells, compared to single-drug loaded
nanofibers. In a different study, Stanzione et al. [37] used PCL to
encapsulate titanocene trichloride, demonstrating a drug release profile
unrelated to polymer degradation, with potential for local treatment of
cancer. Another research team developed a nanofibrous system based on
PVA nanofibers with dacarbazine encapsulated for recurrent glioblas-
toma treatment. The produced electrospun nanofibers demonstrated a
high drug loading, with sustained drug release and antiproliferative ef-
fect [38].
Although most studies reporting the use of electrospun nanofibers for
cancer theranostics application use magnetic nanoparticles (which will
be discussed further in this review), some authors used gadolinium
complexes as magnetic resonance image (MRI) contrast enhancers. Jin
et al. [32,33] prepared core-shell fibers composed of a PEO core and a
Eudragit S100 shell (Fig. 3 E  G). Eudragit is a pH-sensitive polymer
often used as a coating for oral administration, thus avoiding drug release
in the stomach. These core-shell electrospun fibers were loaded with4
Gd(III) diethylenetriamine pentaacetate hydrate and indomethacin. The
hybrid system demonstrated sustained release at pH 7.4 as opposed to
acidic pH. Additionally, proton relaxivities were similar to those of pure
gadolinium complex, demonstrating the potential application for cancer
colon theranostics (Fig. 3 H).
More detailed information on the application of electrospun nano-
fibers in localized cancer treatment can be found in Refs. [6,7,25].
Electrospun nanofibers can also be used as biosensing platforms for
cancer diagnostic. Recently, electrospun nanofibers functionalized with a
specific marker are being used for early detection of circulating tumor
cells (CTCs) [39]. Chen et al. [40] produced TiO2 nanofibers by elec-
trospinning, followed by calcination. The TiO2 nanofibers were func-
tionalized with bovine serum albumin (BSA) to inhibit non-target cell
adhesion, and a specific peptide (asparagine-glycine-arginine –NGR)was
used to capture the target CTCs. The results demonstrated a high capture
sensitivity and efficiency using low concentrations of CTCs in simulated
blood samples. In a different work, PLGA nanofibers were functionalized
with streptavidin for specific detection of biotinylated ant-CD45 anti-
body-labeled white blood cells. Demonstrating a high capture efficiency,
the microfluidic platform integrated with functionalized nanofibers
produces a negative sorting device for early detection of non-small cell
lung cancer [41].
3. Magnetic nanoparticles for cancer theranostics
In the last decades, nanotechnology has revolutionized the develop-
ment of new materials with potential applications in various fields. For
biomedical applications, nanotechnology is used to design and engineer
new devices, particularly for precision medicine. These nano-devices aim
to improve diagnostic precision and treatment outcomes [42]. Typically,
nanoparticles, defined as nanostructures with at least one dimension
below 100 nm, are used to produce nano-devices for biomedical appli-
cations [43]. The ability of mNPs to respond to the application of an
external magnetic field enables their use in nano-devices for a multitude
of biomedical applications [4]. Magnetic nanoparticles can be composed
of pure metals, their oxides, or metal alloys. mNPs of pure metals usually
present higher magnetization than metal oxide ones. However, these
pure metal mNPs are highly sensitive to oxidation andmay be toxic to the
biological systems [10,12]. Magnetic alloys are typically composed of
iron or cobalt with another metal to enhance the magnetization of the
final mNP. Nevertheless, the magnetic properties of alloy mNPs areFig. 3. A) SEM images of PEG-PLA nano-
fibers loaded with DOX 3 wt%; the presence
of DOX at the fiber core was confirmed by
confocal microscopy (B) (Adapted from
Ref. [29] with permission from Elsevier). C)
SEM image of electrospun fibers composed of
quaternized chitosan and PLA loaded with
DOX 6 wt%; in this case, the presence of DOX
was confirmed by fluorescence microscopy
(D) (Adapted from Ref. [31], Copyright
(2010) American Chemical Society). E)
Schematic representation of the production
of core-shell nanofibers composed of Eudra-
git S100 shell and PEO core, and its appli-
cability for oral administration (Reprinted
from Ref. [32], Copyright (2016) American
Chemical Society); F) SEM and G) Trans-
mission electron microscopy (TEM) images
of the core-shell pH-sensitive nanofibers; H)
Core-shell nanofibers under UV irradiation
following immersion in different pH condi-
tions; rhodamine B was used as a model to
illustrate enhanced release at pH 7.4
(Adapted with permission from Ref. [33],
Copyright (2016) John Wiley and Sons).
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synthesis method [12]. Metal oxide NPs are typically chosen for
biomedical applications due to their superparamagnetic properties,
biocompatibility, and chemical stability under physiological environ-
ment. Metal oxide mNPs containing iron include magnetite (Fe3O4),
maghemite (γ-Fe2O3), and other ferrites (MFe2O4, whereM¼ Co, Mn, Ni,
Zn, among others). Particularly for cancer theranostics application,
superparamagnetic properties are preferable. A superparamagnetic NP
rapidly changes its magnetic state upon application of an external
alternating magnetic field; once the field is removed, the mNP have zero
coercivity and present no hysteresis. This phenomenon occurs below a
critical size, where the particle behaves like a paramagnet instead of
individual atomic magnetic moments [10,44].
3.1. Preparation of magnetic nanoparticles
Magnetic nanoparticles can be synthesized using different ap-
proaches, from chemical methods (chemical co-precipitation, thermal
decomposition, hydrothermal synthesis, among others) to physical
methods [4], including laser pyrolysis techniques [45], microorganism or
bacterial synthesis [46]. Chemical methods are usually preferred to
obtain nanometric monodisperse magnetic nanoparticles with adequate
surface chemistry and magnetic properties for biomedical applications
[10]. A recent new method for mNPs synthesis is by using a microfluidic
device. Using these systems, it is possible to obtain 4 nm mNPs with
narrow size distribution due to an efficient control over the reaction
parameters [47].
Following synthesis, mNPs designed for biomedical applications
typically require a coating step to achieve the required colloidal stability
in an aqueous environment. Due to their nanometric size, mNPs tend to
aggregate or agglomerate in an aqueous medium, which predominantly
affects their magnetic properties. To avoid this undesired consequence,
mNPs are typically stabilized using different types of molecules,
including small organic molecules (e.g., oleic acid), macromolecules
(both natural – chitosan- or synthetic - PVA), and inorganic materials
(e.g., silica). In addition to prevent aggregation or agglomeration, mNPs
coating can also be used for further functionalization with a bioactive
agent, thus conferring additional functionality to the nanosystem [4,48].
3.2. Application in cancer theranostics
The unique magnetic properties of iron oxide nanoparticles, partic-
ularly superparamagnetism, are one of the most attractive features for
their application in cancer theranostics. In this sense, three main func-
tionalities are found in mNPs for cancer theranostics application: contrast
agents for MRI, treatment through magnetic hyperthermia, and magnetic
drug delivery. MRI is extensively used for cancer diagnostics by
measuring the nuclear relaxation of atoms in the body following the
application of a strong magnetic field. Using this diagnostic technique, it
is possible to differentiate soft tissue and observe physiological phe-
nomena using a non-invasive method. Superparamagnetic nanoparticles
can enhance the nuclear relaxation of water protons, mainly by changing
the transverse (T2) relaxation, leading to a darker contrast [49]. Several
formulations of iron oxide nanoparticles were clinically approved for
cancer diagnostic through MRI in the last decades. The primary approved
applications included liver and spleen (Feridex I.V.® – USA and
Endorem™ – Europe), lymph node, bone marrow, carotid atherosclerotic
plaques (Sinerem®/Combidex®) imaging. Some formulations were also
clinically approved for MRI imaging through oral administration, mainly
directed for bowel imaging (Lumirem®, GastroMARK®, Abdoscan®).
However, these formulations were withdrawn from the market recently
due to low competitiveness compared to gadolinium-based contrast
agents [50–52].
Magnetic hyperthermia is based on applying an alternating magnetic
field to a tumoral area containing magnetic nanoparticles. The alter-
nating magnetic field induces heat generation by mNPs, which is5
instantly transferred to the tumor cells. If the temperature is maintained
at a temperature above 42 C for sufficient time, tumoral cells will be
destroyed [53,54]. Since 2010, a formulation containing 15 nm iron
oxide nanoparticles coated with aminosilane (Nanotherm®) was
approved for the treatment of glioblastoma multiform by magnetic hy-
perthermia in the European Union. The rationale for Nanotherm®
application is by direct injection in the glioblastoma tumor, followed by
application of an external alternating magnetic field until a temperature
of about 44.6 C is achieved. Simultaneously, clinical trials are being
performed in Europe and the USA to use the same formulation for
pancreatic, prostate, breast, and esophageal cancer treatment [55–58].
Current chemotherapeutic regimens are usually administrated via
intravenous injection, leading to systemic distribution. The presence of
such toxic drugs in healthy cells and tissues leads to adverse side effects.
Drug delivery systems aim to deliver the drug precisely to the target site,
therefore avoiding systemic distribution. mNPs application in drug de-
livery systems takes advantage of the magnetic responsiveness to control
the release of the drug [59]. Typically, an external high-gradient mag-
netic field directs the magnetic nanosystem to the target site. Using this
technique, magnetic nanosystems demonstrated a higher accumulation
in the tumor site in mice bearing CT26 colon carcinomas [60] and lung
tissue [61].
4. Magnetic nanofibers for cancer theranostics
A critical issue when designingmagnetic nanoparticles for biomedical
applications is their biological fate following intravenous injection.
Typically, mNPs are internalized by cells via endocytosis, followed by
degradation in lysosomes, resulting in the release of metal ions. When
using iron oxide nanoparticles, the iron ions are eliminated via endoge-
nous iron metabolism pathways [62,63]. Depending on their size and
surface properties, mNPs can be rapidly eliminated from the bloodstream
following intravenous injection. To avoid particle loss before reaching
the target site and to ensure a high concentration of mNPs suitable for
cancer theranostics application, mNPs can be incorporated into nano-
structured systems. These nanostructured systems can be directly
implanted or injected into the tumor site, ensuring a localized treatment,
thus decreasing negative side-effects to healthy tissues [4].
Nanofiber polymeric membranes incorporating magnetic nano-
particles possess the polymeric matrix's mechanical properties but the
ability to respond to a static or alternating magnetic field. Furthermore,
confining magnetic nanoparticles into a polymeric fiber produces a
multi-core system, i.e., the polymeric nanofibers contain multiple mag-
netic cores incorporated. Therefore, the number of incorporated particles
and their magnetic properties do not change over time, thus ensuring a
constant response to an external magnetic field during the treatment
interval [64].
Electrospinning technique constitutes a simple technique to incor-
porate inorganic nanoparticles directly inside a polymeric matrix. It en-
ables the possibility of simultaneously processing a mixture of different
polymers, or of polymers and small organic molecules as, for example, a
drug. Therefore, the composition and properties of the final nanofibrous
membrane can be easily tunned during electrospinning, including me-
chanical properties, porosity, and swelling, among others [64].
4.1. Natural polymer-based nanofibers
Different types of polymers can be used to incorporate magnetic
nanoparticles, from natural polymers to synthetic ones. Chitosan, a
biopolymer derived from chitin, was used by Lin et al. [65,66] to produce
magnetic nanofibers. The authors evaluated the effects of mNPs location
in heat generation during magnetic hyperthermia assays (Fig. 4 A, B).
The results demonstrated that these non-cytotoxic magnetic nanofibers
could increase the temperature up to 45 C, therefore having potential for
cancer treatment (Fig. 4 C). Radmansouri et al. [67] also used chitosan
nanofibers to encapsulate titanium oxide and cobalt ferrite. These
Fig. 4. A, B) SEM image of magnetic fibers
composed of chitosan and iron oxide nanoparticles
with different preparation methods; C) magnetic
hyperthermia results demonstrate chitosan magnetic
nanofibers' ability to achieve and maintain a hy-
perthermic temperature (Adapted from Ref. [65]
with permission from Elsevier). D, E) SEM and TEM
images of cellulose acetate nanofibers containing
iron oxide nanoparticles adsorbed at fiber surface
and incorporated inside the fibers, respectively; F)
magnetic hyperthermia results enhancing the
importance of mNPs location in the generated heat
when an alternating magnetic field is applied
(Adapted from Ref. [70] with permission from
Elsevier). G) SEM image of PLA nanofibers con-
taining multi-walled carbon nanotubes and iron
oxide nanoparticles; H) K562 cell viability after
synergistic treatment of daunorubicin release and
magnetic hyperthermia, demonstrating the effect of
application of an alternating magnetic field
(Adapted from Ref. [71], Copyright (2016), with
permission from Taylor & Francis Ldt.).
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rubicin release was enhanced by applying an alternating magnetic field,
leading to in vitro cell death using melanoma cancer B16F10 cell lines.
Chitosan is often used in combination with synthetic polymers such as
PCS. Amini et al. [68] produced CS-grafted-PCL nanofibers using elec-
trospinning. Theses nanofibers were loaded with plain bioactive glass
(BG) and magnetic bioactive glass (MBG) together with cisplatin. These
composite nanofibers were evaluated for combinatory treatment of
chemotherapy and magnetic hyperthermia in MG-63 osteosarcoma cells.
The results demonstrated an absence of cisplatin burst release from the
composite nanofibers, whereas a controlled released occurred tailored by
temperature and pH. The fastest release rate was observed at 43 C and
pH of 5.5, demonstrating the synergistic effect of heat generation by
mNPs and drug release. Abasalta et al. [69] used a combination of car-
boxymethyl CS and PCL to produce core-shell nanofiebrs through elec-
trospinning incorporating doxorubicin and nichel ferrite. The results6
demonstrated a sustained DOX release tailored by pH and magnetic field
presence, with promising results for breast cancer treatment.
Using a cellulose derivative, cellulose acetate, Matos et al. [70] pro-
duced magnetic fibers by incorporating or adsorbing magnetite nano-
particles in the biopolymer nanofibers (Fig. 4 D, E). The magnetic
nanofibers demonstrated outstanding potential for cancer treatment
through magnetic hyperthermia, with a significant enhancement of the
generated heat when mNPs are adsorbed at the fiber surface (Fig. 4 F).
As above-mentioned, PLA is a commonly used polymer to produce
electrospun nanofibers for cancer theranostics applications. Hosseini
et al. [71] used PLA electrospun nanofibers incorporated with
multi-walled carbon nanotubes and magnetite nanoparticles for leuke-
mia K562 cancer cells (Fig. 4 G). The authors used daunorubicin as a
model drug and demonstrated in vitro a synergistic cytotoxic effect be-
tween localized chemotherapeutic treatment and an applied magnetic
field (Fig. 4 H). Using a different approach, Awada et al. [72]Fig. 5. Photograph (A) and SEM image (B) of
the polymeric blend composed of PLGA, PLA,
and PCL; C) Schematic representation of the
data model used to produce the most effi-
cient polymeric blend, depending on initial
drug release data; D) Photograph of poly-
meric mesh implantation, and the respective
T2-weighted MR images of the polymeric
mesh implanted in orthotopic rat glioma over
throughout three-months (Reproduced with
permission from Ref. [75], Copyright (2017)
Springer Nature, CC BY 4.0).
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controlled anchoring of mNPs. The obtained magnetic nanofibers
exhibited a core-shell structure with mNPs located at the nanofiber sur-
face. Thoroughly characterization showed that the size and nature of
mNPs were not altered during grafting, thus avoiding undesired aggre-
gation of mNPs inside the fiber. Preliminary in vitro results demonstrated
that these magnetic nanofibers are not cytotoxic and can be used to
enhance T2 contrast in MRI. Perera et al. [73] used the infusion gyration
technique, a spinning technique alternative to electrospinning, to pro-
duce magnetic PVA nanofibers. Using acetaminophen as a model drug,
the authors could control drug release using magnetic actuation. Niko-
laou et al. [74] used PLLA and PEO incorporated with oleic acid-coated
Fe3O4 NPs to produce microrods through electrospinning technique.
These microrods can bemagnetically guided to achieve higher deposition
in selected areas within the lung. Additionally, these magnetic microrods
enable localized lung cancer treatment through a combination of mag-
netic hyperthermia and chemotherapy. Ramachandran et al. [75] per-
formed a systematic study to produce an electrospinning nanofibrous
membrane from a blend of three polymers: PLGA, PLA and PCL (Fig. 5 A,
B). The authors studied different polymer ratios with temozolomide
incorporated. Each blend was tested in orthotopic brain-tumor to eval-
uate drug release kinetics. Different release kinetics were obtained
depending on polymer ratio, from hours to months (Fig. 5 C). In vivo
results in orthotopic rat glioma demonstrated a sustained release over
one month with negligible release to peripherical blood. Additional, over
85% of rats had a long-term survival. Additionally, the presence of mNPs
in the polymeric blends allowed treatment monitoring by MRI (Fig. 5 D,7
E).
4.2. Synthetic polymer-based nanofibers
Tiwari et al. [76] used PCL, an FDA-approved semi-crystalline poly-
mer, to produce magnetic nanofibers for combined chemotherapy and
thermotherapy (Fig. 6A–C). The nanosystem included carbogenic quan-
tum dots as the detection component, and doxorubicin as a model drug,
in addition to iron oxide nanoparticles as the magnetic component. With
an alternating magnetic field application, over 90% of HeLa cells died
through a combination of the generated heat and induced drug release.
The synergistic effect of these magnetic nanofibers as compared to in-
dividual treatments demonstrated the potential for cancer treatment. In
2018, Demir et al. [77] produced PCL magnetic nanofibers with a high
load of mNPs (Fig. 6D–F) and compared the incorporation of a hydro-
phobic (Nile Red) and a hydrophilic (Rhodamine-B) dye. The results
showed that the presence of mNPs influenced dye release, particularly of
the hydrophilic one. However, no significant differences were observed
for the hydrophobic drug. Niiyama et al. [78] went further in this topic
and developed PCL electrospun fibers loaded with magnetic nano-
particles and paclitaxel as an implantable system. This nanofibrous sys-
tem was implanted in tumor-bearing mice (NCI–H23 cells),
demonstrating that the composite system delivers a more effective syn-
ergistic treatment than paclitaxel or heating alone (Fig. 6G–J).
More recently, Suneet et al. [79] produced magnetic electrospun PCL
fibers to produce a bandage for skin cancer treatment. In vitro results
using HeLa cells demonstrated a high efficiency in cancer treatmentFig. 6. A - C) SEM image of PCL magnetic nano-
fibers produced by electrospinning with different
surface textures: smooth, rough, and porous,
respectively. Scale bar 20 μm (Adapted with
permission from Ref. [76]. Copyright (2016) John
Wiley and Sons). D – F) SEM image of PCL nano-
fibers with increasing amounts of mNPs: 1:25, 4:25
and 16:25 (mNP:PCL weight ratio) (Adapted with
permission from Ref. [77], Copyright (2018)
Springer Nature). G, H) Photograph and SEM image
of PCL nanofibrous membrane with mNPs and
paclitaxel incorporated; I) scheme of the in vivo
protocol performed to evaluate the magnetic mem-
branes efficacy for cancer treatment using
tumor-bearing mice; J) Ex vivo photographs of
resected tumors from tumor-bearing mice following
60-days of combinatory thermo and chemotherapy
using the magnetic PCL membranes (Adapted with
permission from Ref. [78], Copyright (2019) John
Wiley and Sons).
Fig. 7. A) TEM image of PNIPAAm microgel con-
taining iron oxide nanoparticles; these hybrid
microgels were confined in PVP nanofibers through
colloidal electrospinning (B) and demonstrated po-
tential for magnetic hyperthermia application (C)
(Adapted with permission from Ref. [83], Copyright
(2021) MDPI, CC BY 4.0). D, E) SEM and TEM image
of nanofibers from a co-polymer of NIPAAm and
HMAAm containing mNPs; this system demon-
strated an on-off switchable and reversible heat
profile when an alternating magnetic field is
applied, associated with a significant change in its
swelling ratio because of the thermoresponsiveness
of the co-polymer; DOX release occurs as a conse-
quence of the swelling ratio change (F) (Adapted
with permission from Ref. [86]. Copyright (2013)
John Wiley and Sons). G, H) SEM and TEM images
of nanofibers from a co-polymer of NIPAAm and
HMAAm containing mNPs, mesoporous silica
nanoparticles, and metformin (MET); this system
also demonstrated a reversible heating profile as a
consequence of the application of an alternating
magnetic field. The consequent changes in the
polymeric fiber swelling ratio led to a controlled
MET release (Adapted from Ref. [87] with permis-
sion from Elsevier).
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[80] incorporated DOX and Fe3O4 nanocubes in electrospun PCL nano-
fibers for combinatorial treatment of cervical cancer. They demonstrated
a synergistic effect between magnetic hyperthermia and chemotherapy
as a promising approach for cervical cancer treatment.
Other synthetic polymers like polyurethane [81], polystyrene [82],
and polyvinyl pyrrolidone (PVP) [83] are also used to produce magnetic
nanofibers by electrospinning. In the latter, thermoresponsive microgels
composed of poly(N-isopropyl acrylamide) (PNIPAAm) containing mNPs
were incorporated using the colloidal electrospinning technique (Fig. 7
A-C). Colloidal electrospinning is similar to traditional electrospinning,
but instead of a precursor polymeric solution, it uses a precursor colloidal
solution [84,85]. These fibers generated heat under the application of an
alternating magnetic field, thus demonstrating the potential for magnetic
hyperthermia application. The combination of stimuli-responsive poly-
mers with magnetic nanoparticles produces smart systems with8
significant application in cancer theranostics. Kim et al. [86] used a
co-polymer of NIPAAm and N-hydroxymethyl acrylamide (HMAAm) to
produce an on-off system capable of changing its swelling ratio under the
application of an alternating magnetic field (Fig. 7 D-F). The heat gener-
ated from the incorporated magnetic nanoparticles induces the physical
changes in the thermoresponsive polymer. This composite system can be
used as a remotely controlled on-off drug release system. Using the same
thermoresponsive polymer, other research group incorporated bothmNPs
and paclitaxel using electrospinning. The resultant nanofibrous mem-
branedemonstrated synergistic thermo-chemotherapeutic effectswithout
significant adverse side effects inmouse lung cancermodel. Similar results
were obtained in B16F10 skin melanoma cells (Fig. 7 G-I) [87].
In another study, the authors produced novel catecholic nanofibrous
membranes by electrospinning a mussel-inspired polymer (poly(methyl
methacrylate-co dopamine methacrylamide)) (MADO). Following iron
oxide nanoparticles incorporation, the smart nanofibers were tested forFig. 8. A) Schematic representation of the
pH-responsive magnetic system composed of
Eudragit L100 or S100 containing mNPs for
oral administration and specific delivery at
the colon for cancer theranostics application;
B, C) SEM images of the magnetic nanofibers
produced from Eudragit L100 and S100,
respectively; D) this system releases carmofur
specifically in pH conditions similar to small
intestine and colon; additionally, the pres-
ence of mNPs allow treatment monitoring
and drug release quantification through MRI,
a non-invasive imaging technique (Repro-
duced from Ref. [90] with permission from
the Royal Society of Chemistry).
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perthermia and chemotherapy. This smart nanosystem could release
bortezomib in a pH-dependent manner while maintaining an efficient
cyclic heating performance. Moreover, these nanofibers can be moni-
tored following direct implantation in the tumor using the MRI modality
[88]. Using the same approach, the authors demonstrated similar results
using PLGA instead of MADO [89].
Zhang et al. [90] used two pH-responsive polymers, Eudragit L100
and S100, co-polymers of methacrylic acid and methyl methacrylate only
soluble in water in a specific range of pH, above pH 6.0 or pH 7.0,
respectively (Fig. 8). These two polymers were electrospun in the pres-
ence of iron oxide nanoparticles, thus protecting the mNPs from the
acidic conditions in gastric fluid. Carmofur, a chemotherapeutic drug
commonly used for colon cancer treatment, was used as model drug. The
results confirmed the protective effect of Eudragit fibers, leading to a
specific release of carmofur in pH conditions similar to those found in the
small intestine and colon. Due to the presence of mNPs, the authors found
a relation between proton relaxation changes and drug release, enabling
drug release quantification through MRI.
4.3. Opportunities and challenges of electrospun magnetic nanofibers
Nowadays cancer is of the major burns of mankind. On the other
hand, precision and personalized approaches are becoming the major
purpose to achieve early diagnostics, effective treatments and minimum
side effects. In this context, a device that can be implanted in a target site,
manipulated externally, and tailored for a specific patient is desired.
Magnetic electrospun nanofibers can be easily implanted in the tumor
site and remotely activated to achieve a personalized treatment. More-
over, the presence of magnetic nanoparticles enables treatment moni-
toring through MRI.
In a different feature, electrospun nanofibers have been recently used
for specialized diagnostic methods such as detection of CTCs in blood,
allowing early detection of cancer. Additionally, functionalization with
specific markers supports the use of electrospun nanofibers in different
biosensoring devices. The major advantages of an electrospun nanofiber-
based system is its flexibility, low cost and large scale production,
biocompatibility, and availability of different polymers that can be
chosen according to the desired application.
Nevertheless, the major limitation of electrospunmagnetic nanofibers
is their early stage of development. Most studies only report in vitro or in
vivo studies. However, several natural-derived or synthetic polymers used
to produce magnetic nanofibers are already approved by the FDA for
other medical applications. Therefore, it is expected a smoother path for
clinical translation of magnetic electrospun nanofibers for cancer thera-
nostics application.
5. Conclusion
Current cancer treatment and diagnostic struggles are to provide the
most efficient course of treatment without causing severe side effects and
to diagnose the disease in its extension as early as possible, also allowing
further treatment monitoring. Therefore, a nanosystem able to combine
both treatment and diagnostic features is ideal to fulfill such purposes.
Electrospun polymeric nanofibers have demonstrated to be effective
vehicles for long-term local chemotherapeutic drugs release, thus pre-
venting severe side effects and cancer recurrence. The addition of mag-
netic features in the form of magnetic nanoparticles enables additional
functionalities. First, thermotherapy and chemotherapy can be combined
locally, often resulting in a synergistic therapeutic effect. Second, the
magnetic nanosystem can be remotely controlled, acting as an on-off
switch. Third, the presence of mNPs allows treatment monitoring by
MRI, even allowing the quantification of the released drug in some cases.
These hybrid nanosystems are still not clinically approved for cancer
theranostics. However, current research includes numerous in vitro and in
vivo results that demonstrate the high potential of electrospun magnetic/9
polymeric nanofibers for cancer theranostics application.
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